Limits...
Multiple treatment comparisons in epilepsy monotherapy trials.

Tudur Smith C, Marson AG, Chadwick DW, Williamson PR - Trials (2007)

Bottom Line: The choice of antiepileptic drug for an individual should be based upon the highest quality evidence regarding potential benefits and harms of the available treatments.For patients with partial onset seizures, results favour carbamazepine, oxcarbazepine and lamotrigine.For generalized onset tonic clonic seizures, results favour valproate and phenytoin.

View Article: PubMed Central - HTML - PubMed

Affiliation: Centre for Medical Statististcs and Health Evaluation, University of Liverpool, Liverpool, UK. cat1@liv.ac.uk

ABSTRACT

Background: The choice of antiepileptic drug for an individual should be based upon the highest quality evidence regarding potential benefits and harms of the available treatments. Systematic reviews and meta-analysis of randomised controlled trials should be a major source of evidence supporting this decision making process. We summarise all available individual patient data evidence from randomised controlled trials that compared at least two out of eight antiepileptic drugs given as monotherapy.

Methods: Multiple treatment comparisons from epilepsy monotherapy trials were synthesized in a single stratified Cox regression model adjusted for treatment by epilepsy type interactions and making use of direct and indirect evidence. Primary outcomes were time to treatment failure and time to 12 month remission from seizures. A secondary outcome was time to first seizure.

Results: Individual patient data for 6418 patients from 20 randomised trials comparing eight antiepileptic drugs were synthesized. For partial onset seizures (4628 (72%) patients), lamotrigine, carbamazepine and oxcarbazepine provide the best combination of seizure control and treatment failure. Lamotrigine is clinically superior to all other drugs for treatment failure but estimates suggest a disadvantage compared to carbamazepine for time to 12 month remission [Hazard Ratio (95% Confidence Interval) = 0.87(0.73 to 1.04)] and time to first seizure [1.29(1.13 to 1.48)]. Phenobarbitone may delay time to first seizure [0.77(0.61 to 0.96)] but at the expense of increased treatment failure [1.60(1.22 to 2.10)]. For generalized onset tonic clonic seizures (1790 (28%) patients) estimates suggest valproate or phenytoin may provide the best combination of seizure control and treatment failure but some uncertainty remains about the relative effectiveness of other drugs.

Conclusion: For patients with partial onset seizures, results favour carbamazepine, oxcarbazepine and lamotrigine. For generalized onset tonic clonic seizures, results favour valproate and phenytoin.

No MeSH data available.


Related in: MedlinePlus

Time to first seizure for partial onset seizures (Hazard Ratio for each AED compared to standard CBZ). CBZ: Carbamazepine, VPA: Sodium Valproate, PHT: Phenytoin, PB: Phenobarbitone, LTG: Lamotrigine, OXC: Oxcarbazepine, GBP: Gabapentine, TPM: Topirimate
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2194733&req=5

Figure 3: Time to first seizure for partial onset seizures (Hazard Ratio for each AED compared to standard CBZ). CBZ: Carbamazepine, VPA: Sodium Valproate, PHT: Phenytoin, PB: Phenobarbitone, LTG: Lamotrigine, OXC: Oxcarbazepine, GBP: Gabapentine, TPM: Topirimate

Mentions: Analyses adjusted for treatment and epilepsy type main effects and their interaction are displayed in Figures 1, 2, 3, 4, 5, 6 for each outcome based on the multiple treatment comparisons analysis of all relevant trials for which data are available. Each figure presents a hazard ratio and 95% confidence interval for every AED compared with the current standard (CBZ for partials and VPA for generalised) ordered by size of effect. Each box represents a point estimate of hazard ratio with the size of each box inversely proportional to the width of the 95% confidence interval for the relevant hazard ratio.


Multiple treatment comparisons in epilepsy monotherapy trials.

Tudur Smith C, Marson AG, Chadwick DW, Williamson PR - Trials (2007)

Time to first seizure for partial onset seizures (Hazard Ratio for each AED compared to standard CBZ). CBZ: Carbamazepine, VPA: Sodium Valproate, PHT: Phenytoin, PB: Phenobarbitone, LTG: Lamotrigine, OXC: Oxcarbazepine, GBP: Gabapentine, TPM: Topirimate
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2194733&req=5

Figure 3: Time to first seizure for partial onset seizures (Hazard Ratio for each AED compared to standard CBZ). CBZ: Carbamazepine, VPA: Sodium Valproate, PHT: Phenytoin, PB: Phenobarbitone, LTG: Lamotrigine, OXC: Oxcarbazepine, GBP: Gabapentine, TPM: Topirimate
Mentions: Analyses adjusted for treatment and epilepsy type main effects and their interaction are displayed in Figures 1, 2, 3, 4, 5, 6 for each outcome based on the multiple treatment comparisons analysis of all relevant trials for which data are available. Each figure presents a hazard ratio and 95% confidence interval for every AED compared with the current standard (CBZ for partials and VPA for generalised) ordered by size of effect. Each box represents a point estimate of hazard ratio with the size of each box inversely proportional to the width of the 95% confidence interval for the relevant hazard ratio.

Bottom Line: The choice of antiepileptic drug for an individual should be based upon the highest quality evidence regarding potential benefits and harms of the available treatments.For patients with partial onset seizures, results favour carbamazepine, oxcarbazepine and lamotrigine.For generalized onset tonic clonic seizures, results favour valproate and phenytoin.

View Article: PubMed Central - HTML - PubMed

Affiliation: Centre for Medical Statististcs and Health Evaluation, University of Liverpool, Liverpool, UK. cat1@liv.ac.uk

ABSTRACT

Background: The choice of antiepileptic drug for an individual should be based upon the highest quality evidence regarding potential benefits and harms of the available treatments. Systematic reviews and meta-analysis of randomised controlled trials should be a major source of evidence supporting this decision making process. We summarise all available individual patient data evidence from randomised controlled trials that compared at least two out of eight antiepileptic drugs given as monotherapy.

Methods: Multiple treatment comparisons from epilepsy monotherapy trials were synthesized in a single stratified Cox regression model adjusted for treatment by epilepsy type interactions and making use of direct and indirect evidence. Primary outcomes were time to treatment failure and time to 12 month remission from seizures. A secondary outcome was time to first seizure.

Results: Individual patient data for 6418 patients from 20 randomised trials comparing eight antiepileptic drugs were synthesized. For partial onset seizures (4628 (72%) patients), lamotrigine, carbamazepine and oxcarbazepine provide the best combination of seizure control and treatment failure. Lamotrigine is clinically superior to all other drugs for treatment failure but estimates suggest a disadvantage compared to carbamazepine for time to 12 month remission [Hazard Ratio (95% Confidence Interval) = 0.87(0.73 to 1.04)] and time to first seizure [1.29(1.13 to 1.48)]. Phenobarbitone may delay time to first seizure [0.77(0.61 to 0.96)] but at the expense of increased treatment failure [1.60(1.22 to 2.10)]. For generalized onset tonic clonic seizures (1790 (28%) patients) estimates suggest valproate or phenytoin may provide the best combination of seizure control and treatment failure but some uncertainty remains about the relative effectiveness of other drugs.

Conclusion: For patients with partial onset seizures, results favour carbamazepine, oxcarbazepine and lamotrigine. For generalized onset tonic clonic seizures, results favour valproate and phenytoin.

No MeSH data available.


Related in: MedlinePlus